Emre M Isin

Summary

Affiliation: AstraZeneca R and D

Publications

  1. pmc Substrate binding to cytochromes P450
    Emre M Isin
    Biotransformation Section, Department of Discovery DMPK and Bioanalytical Chemistry, AstraZeneca R and D Molndal, 431 83, Molndal, Sweden
    Anal Bioanal Chem 392:1019-30. 2008
  2. doi request reprint Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies
    Emre M Isin
    CVGI iMED DMPK, ADME Section, Centre of Excellence, AstraZeneca R and D, Molndal, SE 431 83 Sweden
    Chem Res Toxicol 25:532-42. 2012
  3. doi request reprint In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs
    Richard A Thompson
    DMPK Innovative Medicine, AstraZeneca, Molndal, 431 83, Sweden
    Chem Res Toxicol 25:1616-32. 2012
  4. doi request reprint Database Extraction of Metabolite Information of Drug Candidates: Analysis of 27 AstraZeneca Compounds with Human Absorption, Distribution, Metabolism, and Excretion Data
    Jessica Iegre
    Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit J I, M A H, L W, E M I and Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development Biotech Unit R A T, AstraZeneca, Molndal, Sweden
    Drug Metab Dispos 44:732-40. 2016
  5. ncbi request reprint Model electrochemical-mass spectrometric studies of the cytochrome P450-catalyzed oxidations of cyclic tertiary allylamines
    Ulrik Jurva
    Department of DMPK and Bioanalytical Chemistry, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    J Am Chem Soc 127:12368-77. 2005
  6. doi request reprint Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development
    Richard A Thompson
    Discovery DMPK, AstraZeneca R and D Molndal, SE 413 83 Mölndal, Sweden
    Chem Biol Interact 192:65-71. 2011
  7. doi request reprint Reactive Metabolites: Current and Emerging Risk and Hazard Assessments
    Richard A Thompson
    DMPK, Respiratory, Inflammation and Autoimmunity iMed, AstraZeneca R and D, 431 83 Mölndal, Sweden
    Chem Res Toxicol 29:505-33. 2016
  8. doi request reprint Use of electrochemical oxidation and model peptides to study nucleophilic biological targets of reactive metabolites: the case of rimonabant
    Annika Thorsell
    DMPK Design and Biotransformation, CVMD iMed DMPK, AstraZeneca R and D Molndal, Sweden, Pepparedsleden 1, SE 431 83, Molndal, Sweden
    Chem Res Toxicol 27:1808-20. 2014
  9. doi request reprint Bioactivation pathways of the cannabinoid receptor 1 antagonist rimonabant
    Moa Andresen Bergström
    CVGI iMED DMPK, AstraZeneca R and D Molndal, SE 43183 Mölndal, Sweden
    Drug Metab Dispos 39:1823-32. 2011

Collaborators

Detail Information

Publications9

  1. pmc Substrate binding to cytochromes P450
    Emre M Isin
    Biotransformation Section, Department of Discovery DMPK and Bioanalytical Chemistry, AstraZeneca R and D Molndal, 431 83, Molndal, Sweden
    Anal Bioanal Chem 392:1019-30. 2008
    ..Some of the substrate binding studies extending over a period of more than 40 years of dedicated work have been summarized in this review and categorized by the techniques employed in the binding studies...
  2. doi request reprint Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies
    Emre M Isin
    CVGI iMED DMPK, ADME Section, Centre of Excellence, AstraZeneca R and D, Molndal, SE 431 83 Sweden
    Chem Res Toxicol 25:532-42. 2012
    ..Finally, we outline strategic changes to our use of radiolabeled compounds in drug metabolism and pharmacokinetic studies, with an emphasis on delaying of in vivo studies employing radiolabeled drug molecules...
  3. doi request reprint In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs
    Richard A Thompson
    DMPK Innovative Medicine, AstraZeneca, Molndal, 431 83, Sweden
    Chem Res Toxicol 25:1616-32. 2012
    ....
  4. doi request reprint Database Extraction of Metabolite Information of Drug Candidates: Analysis of 27 AstraZeneca Compounds with Human Absorption, Distribution, Metabolism, and Excretion Data
    Jessica Iegre
    Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit J I, M A H, L W, E M I and Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development Biotech Unit R A T, AstraZeneca, Molndal, Sweden
    Drug Metab Dispos 44:732-40. 2016
    ..This retrospective analysis assesses the predictive value of Met-ID experiments and improves our ability to discriminate between metabolites expected to circulate in humans and irrelevant metabolites seen in preclinical studies. ..
  5. ncbi request reprint Model electrochemical-mass spectrometric studies of the cytochrome P450-catalyzed oxidations of cyclic tertiary allylamines
    Ulrik Jurva
    Department of DMPK and Bioanalytical Chemistry, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    J Am Chem Soc 127:12368-77. 2005
    ....
  6. doi request reprint Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development
    Richard A Thompson
    Discovery DMPK, AstraZeneca R and D Molndal, SE 413 83 Mölndal, Sweden
    Chem Biol Interact 192:65-71. 2011
    ..We exemplify the potential value of this approach by consideration of the thiazolidinedione class of drugs...
  7. doi request reprint Reactive Metabolites: Current and Emerging Risk and Hazard Assessments
    Richard A Thompson
    DMPK, Respiratory, Inflammation and Autoimmunity iMed, AstraZeneca R and D, 431 83 Mölndal, Sweden
    Chem Res Toxicol 29:505-33. 2016
    ..Finally, the potential impact of systems pharmacology approaches in reactive metabolite risk assessments is highlighted. ..
  8. doi request reprint Use of electrochemical oxidation and model peptides to study nucleophilic biological targets of reactive metabolites: the case of rimonabant
    Annika Thorsell
    DMPK Design and Biotransformation, CVMD iMed DMPK, AstraZeneca R and D Molndal, Sweden, Pepparedsleden 1, SE 431 83, Molndal, Sweden
    Chem Res Toxicol 27:1808-20. 2014
    ....
  9. doi request reprint Bioactivation pathways of the cannabinoid receptor 1 antagonist rimonabant
    Moa Andresen Bergström
    CVGI iMED DMPK, AstraZeneca R and D Molndal, SE 43183 Mölndal, Sweden
    Drug Metab Dispos 39:1823-32. 2011
    ..In view of these findings, it is noteworthy that, to date, no toxicity findings related to the formation of reactive metabolites from rimonabant have been reported...